Caroline Boursier1,2, Xavier Duval3,4,5, Besma Mahida6, Bruno Hoen7,8, François Goehringer8, Christine Selton-Suty9, Elodie Chevalier10, Véronique Roch10, Zohra Lamiral11, Aurélie Bourdon12, Nicolas Piriou13, Amandine Pallardy13, Olivier Morel14, François Rouzet6,15, Pierre-Yves Marie7,10,16. 1. Université de Lorraine, 54000, Nancy, France. c.boursier@chru-nancy.fr. 2. Department of Nuclear Medicine and Nancyclotep Molecular Imaging Platform, CHRU-Nancy, 54000, Nancy, France. c.boursier@chru-nancy.fr. 3. Université Paris Diderot, INSERM, UMR 1137 (IAME), 75000, Paris, France. 4. INSERM, CIC 1425, AP-HP, Hôpital Bichat Claude Bernard, 75000, Paris, France. 5. Department of Infectious Diseases, AP-HP, Hôpital Bichat Claude Bernard, 75000, Paris, France. 6. Department of Nuclear Medicine, AP-HP, Hôpital Bichat Claude Bernard, 75000, Paris, France. 7. Université de Lorraine, 54000, Nancy, France. 8. Department of Infectious Diseases, CHRU-Nancy, 54000, Nancy, France. 9. Department of Cardiology, CHRU-Nancy, 54000, Nancy, France. 10. Department of Nuclear Medicine and Nancyclotep Molecular Imaging Platform, CHRU-Nancy, 54000, Nancy, France. 11. Université de Lorraine, CHRU-Nancy, INSERM, CIC 1433, 54000, Nancy, France. 12. Department of Nuclear Medicine, Montpellier University Hospital, 34000, Montpellier, France. 13. Department of Nuclear Medicine, CHU de Nantes, 44000, Nantes, France. 14. CHU-Besançon, Université de Franche-Comté, Service de Médecine Nucléaire, 25000, Besançon, France. 15. Université Paris Diderot, INSERM, UMR 1148 (LVTS), 75000, Paris, France. 16. Université de Lorraine, INSERM, UMR 1116, 54000, Nancy, France.
Abstract
PURPOSE: This study aimed at determining the diagnostic implications of indirect signs of infection at FDG-PET-i.e., hypermetabolisms of the spleen and/or bone marrow (HSBM)-when documented in patients with known or suspected infective endocarditis (IE). METHODS: HSBM were defined by higher mean standardized uptake values comparatively to that of the liver on FDG-PET images from patients with a high likelihood of IE and prospectively included in a multicenter study. RESULTS: Among the 129 included patients, IE was ultimately deemed as definite in 88 cases. HSBM was a predictor of definite IE (P = 0.014; odds ratio (OR) 3.2), independently of the criterion of an abnormal cardiac FDG uptake (P = 0.0007; OR 9.68), and a definite IE was documented in 97% (29/30) of patients showing both HSBM and abnormal cardiac uptake, 78% (7/9) of patients with only abnormal cardiac uptake, 67% (42/63) of patients with only HSBM, and 37% (10/27) of patients with neither one. CONCLUSION: In this cohort with a high likelihood of IE, HSBM is an additional albeit indirect sign of IE, independently of the criterion of an abnormal cardiac uptake, and could reinforce the suspicion of IE in the absence of any other infectious, inflammatory, or malignant disease.
PURPOSE: This study aimed at determining the diagnostic implications of indirect signs of infection at FDG-PET-i.e., hypermetabolisms of the spleen and/or bone marrow (HSBM)-when documented in patients with known or suspected infective endocarditis (IE). METHODS: HSBM were defined by higher mean standardized uptake values comparatively to that of the liver on FDG-PET images from patients with a high likelihood of IE and prospectively included in a multicenter study. RESULTS: Among the 129 included patients, IE was ultimately deemed as definite in 88 cases. HSBM was a predictor of definite IE (P = 0.014; odds ratio (OR) 3.2), independently of the criterion of an abnormal cardiac FDG uptake (P = 0.0007; OR 9.68), and a definite IE was documented in 97% (29/30) of patients showing both HSBM and abnormal cardiac uptake, 78% (7/9) of patients with only abnormal cardiac uptake, 67% (42/63) of patients with only HSBM, and 37% (10/27) of patients with neither one. CONCLUSION: In this cohort with a high likelihood of IE, HSBM is an additional albeit indirect sign of IE, independently of the criterion of an abnormal cardiac uptake, and could reinforce the suspicion of IE in the absence of any other infectious, inflammatory, or malignant disease.
Authors: Ik Dong Yoo; Sang Mi Lee; Jeong Won Lee; Jung Eun Oh; Yong Jin Cho; Hwang Sik Shin Journal: Hell J Nucl Med Date: 2017-11-27 Impact factor: 1.102
Authors: Alberto Signore; Chiara Lauri; Marzia Colandrea; Marco Di Girolamo; Erika Chiodo; Chiara Maria Grana; Giuseppe Campagna; Antonio Aceti Journal: Eur J Nucl Med Mol Imaging Date: 2022-04-29 Impact factor: 10.057